US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Q32 Bio Inc.

7.30

+0.54007.99%

Volume:277.88K

Turnover:1.97M

Market Cap:106.80M

PE:3.02

High:7.37

Open:6.74

Low:6.40

Close:6.76

52wk High:7.80

52wk Low:1.35

Shares:14.63M

Float Shares:9.82M

Volume Ratio:0.84

T/O Rate:2.83%

Dividend:- -

Dividend Rate:- -

EPS(TTM):2.42

EPS(LYR):-5.1211

ROE:125.06%

ROA:13.71%

PB:2.54

PE(LYR):-1.43

Loading ...

Overview Company News Filings

BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097

Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics

Top Premarket Gainers

MT Newswires Live

Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio

Akebia Announces Establishment of Rare Kidney Disease Pipeline

THOMSON REUTERS

Akebia Therapeutics: Phase 2 Basket Trial Planned to Evaluate Complement Inhibitor in Multiple Rare Kidney Disease Indications

THOMSON REUTERS

Akebia Therapeutics Inc: Both Trials Planned to Start Treating Subjects in 2026

THOMSON REUTERS

Akebia Therapeutics: Acquires Next Generation Tissue-Targeted C3d-Factor H Fusion Protein Complement Inhibitor From Q32 Bio

THOMSON REUTERS

Akebia Therapeutics Inc: Phase 2 Trial of Praliciguat Initiated in Focal Segmental Glomerulosclerosis (Fsgs)

THOMSON REUTERS

Q32 Bio Inc - Eligible for up to $592 Mln Including Royalties

THOMSON REUTERS

Q32 Bio Inc - $12 Mln Payments Expected to Extend Cash Runway Into Second Half of 2027

THOMSON REUTERS

Press Release: Q32 Bio Sells Complement Inhibitor ADX-097

Q32 Bio (QTTB) Receives a Buy from Oppenheimer

Wells Fargo Remains a Hold on Q32 Bio (QTTB)

Q32 Bio Inc. reports Q3 net loss of $7.4 million

Q32 Bio Inc - Q3 Net Loss $7.4 Mln

THOMSON REUTERS

Q32 Bio Inc Qtrly EPS $-0.60

THOMSON REUTERS

Q32 Bio Inc: Cash and Cash Equivalents Sufficient to Fund Operations Into 2027

THOMSON REUTERS

Q32 Bio Inc expected to post a loss of $1.19 a share - Earnings Preview

Q32 Bio Completes Enrollment in Phase 2a Alopecia Areata Trial of Bempikibart

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/QTTB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"QTTB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","market":"US","secType":"STK","nameCN":"Q32 Bio Inc.","latestPrice":7.3,"timestamp":1774382400000,"preClose":6.76,"halted":0,"volume":277882,"delay":0,"changeRate":0.07988165680473373,"floatShares":9816335,"shares":14629463,"eps":2.419999,"marketStatus":"Pre-Mkt","change":0.54,"latestTime":"03-25 05:14:18 EDT","open":6.74,"high":7.3699,"low":6.4,"amount":1972004.618628,"amplitude":0.143476,"askPrice":8.03,"askSize":100,"bidPrice":7,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.419999,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774445400000},"marketStatusCode":1,"adr":0,"listingDate":1522209600000,"exchange":"NASDAQ","adjPreClose":7.3,"postHourTrading":{"tag":"盘后","latestPrice":7.31,"preClose":7.3,"latestTime":"18:57 EDT","volume":2182,"amount":16102.6655,"timestamp":1774393037928,"change":0.01,"changeRate":0.00137,"amplitude":0.013699},"volumeRatio":0.837277872905139,"impliedVol":0.4864,"impliedVolPercentile":0.8182},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","floatShares":9816335,"roa":"13.71%","roe":"125.06%","lyrEps":-5.12108,"volumeRatio":0.837277872905139,"shares":14629463,"dividePrice":0,"high":7.3699,"amplitude":0.143476,"preClose":6.76,"low":6.4,"week52Low":1.345,"pbRate":"2.54","psRate":"1.99","week52High":7.8,"institutionHeld":0,"latestPrice":7.3,"eps":2.419999,"divideRate":0,"volume":277882,"delay":0,"ttmEps":2.419999,"open":6.74,"prevYearClose":3.32,"prevWeekClose":6.68,"prevMonthClose":4.56,"prevQuarterClose":3.32,"fiveDayClose":6.13,"twentyDayClose":4.5,"sixtyDayClose":3.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/QTTB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-10","symbol":"QTTB","fiscalQuarterEnding":"2025/12","expectedEps":-0.85,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"pre","actualEps":3.65},{"market":"US","date":"2025-11-13","symbol":"QTTB","fiscalQuarterEnding":"2025/09","expectedEps":-1.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2025-08-06","symbol":"QTTB","fiscalQuarterEnding":"2025/06","expectedEps":-1.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2025-03-11","symbol":"QTTB","fiscalQuarterEnding":"2024/12","expectedEps":-1.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2024-05-09","symbol":"QTTB","fiscalQuarterEnding":"2024/03","expectedEps":-1.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-13.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"QTTB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"QTTB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1772078400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/QTTB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"QTTB","date":"2026-03-23","current":3.01653,"percent":0.993711,"low":-10.694771,"twenty":-6.234829,"median":-0.737399,"eighty":-0.431603,"high":3.453654,"avg":-2.797335,"sd":3.448228,"marketCap":97724812},"quantilePoints":[{"date":"2024-04-05","current":-4.597074,"twenty":-4.75645,"median":-4.597074,"eighty":-3.952906,"marketCap":247060524},{"date":"2024-04-12","current":-5.285192,"twenty":-4.79019,"median":-4.726928,"eighty":-4.38975,"marketCap":284042061},{"date":"2024-04-19","current":-5.411717,"twenty":-5.438798,"median":-4.767993,"eighty":-4.57532,"marketCap":290841892},{"date":"2024-04-26","current":-6.268535,"twenty":-5.702502,"median":-5.138689,"eighty":-4.700069,"marketCap":336889870},{"date":"2024-05-03","current":-5.72026,"twenty":-5.938238,"median":-5.411717,"eighty":-4.727594,"marketCap":307423936},{"date":"2024-05-10","current":-5.948893,"twenty":-5.966207,"median":-5.603724,"eighty":-4.749348,"marketCap":319711350},{"date":"2024-05-17","current":-6.881182,"twenty":-6.171755,"median":-5.72026,"eighty":-4.765329,"marketCap":369815368},{"date":"2024-05-24","current":-6.526024,"twenty":-6.419477,"median":-5.852334,"eighty":-4.856783,"marketCap":350728123},{"date":"2024-05-31","current":-7.119566,"twenty":-6.557988,"median":-5.896729,"eighty":-4.946904,"marketCap":326617228},{"date":"2024-06-07","current":-5.417118,"twenty":-6.655355,"median":-5.948893,"eighty":-5.16799,"marketCap":248515704},{"date":"2024-06-14","current":-5.122964,"twenty":-6.625166,"median":-5.89118,"eighty":-5.079231,"marketCap":235021098},{"date":"2024-06-21","current":-4.172821,"twenty":-6.589953,"median":-5.833467,"eighty":-4.901621,"marketCap":191432327},{"date":"2024-06-28","current":-3.969777,"twenty":-6.557988,"median":-5.738018,"eighty":-4.86516,"marketCap":182117467},{"date":"2024-07-05","current":-4.511228,"twenty":-6.526024,"median":-5.680305,"eighty":-4.760002,"marketCap":206957095},{"date":"2024-07-12","current":-5.841429,"twenty":-6.49406,"median":-5.603724,"eighty":-4.798567,"marketCap":267981374},{"date":"2024-07-15","current":-6.825412,"twenty":-6.526024,"median":-5.660327,"eighty":-4.813855,"marketCap":313122622},{"date":"2024-08-02","current":-9.884093,"twenty":-6.542006,"median":-5.670316,"eighty":-4.829142,"marketCap":453442638},{"date":"2024-08-09","current":-7.500596,"twenty":-6.710706,"median":-5.738018,"eighty":-4.87207,"marketCap":427886482},{"date":"2024-08-16","current":-7.75207,"twenty":-6.825412,"median":-5.856316,"eighty":-4.928392,"marketCap":442232352},{"date":"2024-08-23","current":-8.155846,"twenty":-7.24299,"median":-5.902278,"eighty":-4.94491,"marketCap":465266543},{"date":"2024-08-30","current":-8.295371,"twenty":-7.548702,"median":-6.028804,"eighty":-4.98294,"marketCap":473226002},{"date":"2024-09-06","current":-9.684274,"twenty":-7.772364,"median":-6.120922,"eighty":-4.998807,"marketCap":552458796},{"date":"2024-09-13","current":-9.610284,"twenty":-8.191784,"median":-6.244914,"eighty":-5.018839,"marketCap":548237871},{"date":"2024-09-20","current":-9.971779,"twenty":-8.294103,"median":-6.360654,"eighty":-5.041746,"marketCap":568860105},{"date":"2024-09-27","current":-9.599714,"twenty":-8.935493,"median":-6.526024,"eighty":-5.050076,"marketCap":547634882},{"date":"2024-10-04","current":-9.037388,"twenty":-9.107996,"median":-6.621961,"eighty":-5.093809,"marketCap":515555851},{"date":"2024-10-11","current":-9.978122,"twenty":-9.382394,"median":-6.703603,"eighty":-5.220301,"marketCap":569221899},{"date":"2024-10-18","current":-10.49394,"twenty":-9.484712,"median":-6.794175,"eighty":-5.315929,"marketCap":598647777},{"date":"2024-10-25","current":-10.06691,"twenty":-9.672968,"median":-6.825412,"eighty":-5.346971,"marketCap":574287009},{"date":"2024-10-31","current":-9.792089,"twenty":-9.748541,"median":-7.119566,"eighty":-5.360507,"marketCap":558609287},{"date":"2024-11-08","current":-9.443128,"twenty":-9.802236,"median":-7.283651,"eighty":-5.372344,"marketCap":572357443},{"date":"2024-11-15","current":-7.16039,"twenty":-9.789552,"median":-7.500596,"eighty":-5.379633,"marketCap":433998376},{"date":"2024-11-22","current":-5.434099,"twenty":-9.773909,"median":-7.256318,"eighty":-5.396215,"marketCap":329366155},{"date":"2024-11-29","current":-5.407973,"twenty":-9.752346,"median":-7.139978,"eighty":-5.371303,"marketCap":327782663},{"date":"2024-12-06","current":-4.760865,"twenty":-9.734588,"median":-6.825412,"eighty":-5.339276,"marketCap":288560806},{"date":"2024-12-13","current":-0.854102,"twenty":-9.716407,"median":-6.794175,"eighty":-5.114636,"marketCap":51767979},{"date":"2024-12-20","current":-0.671224,"twenty":-9.680505,"median":-6.703603,"eighty":-5.031844,"marketCap":40683541},{"date":"2024-12-27","current":-0.719455,"twenty":-9.66543,"median":-6.637987,"eighty":-4.975898,"marketCap":43606909},{"date":"2025-01-03","current":-0.69333,"twenty":-9.621313,"median":-6.605935,"eighty":-4.929676,"marketCap":42023418},{"date":"2025-01-10","current":-0.657156,"twenty":-9.603942,"median":-6.526024,"eighty":-4.86516,"marketCap":39830892},{"date":"2025-01-17","current":-0.631031,"twenty":-9.545173,"median":-6.362567,"eighty":-4.746844,"marketCap":38247401},{"date":"2025-01-24","current":-0.677253,"twenty":-9.492745,"median":-6.288512,"eighty":-4.6939,"marketCap":41048962},{"date":"2025-01-31","current":-0.655147,"twenty":-9.465263,"median":-6.219701,"eighty":-4.511228,"marketCap":39709085},{"date":"2025-02-07","current":-0.63505,"twenty":-9.453365,"median":-6.05877,"eighty":-3.980076,"marketCap":38491015},{"date":"2025-02-14","current":-0.538587,"twenty":-9.43896,"median":-5.948893,"eighty":-0.813105,"marketCap":32644278},{"date":"2025-02-21","current":-0.488345,"twenty":-9.423405,"median":-5.89118,"eighty":-0.724279,"marketCap":29599103},{"date":"2025-02-28","current":-0.450162,"twenty":-9.384931,"median":-5.843753,"eighty":-0.704182,"marketCap":27284770},{"date":"2025-03-07","current":-0.468249,"twenty":-9.351106,"median":-5.738018,"eighty":-0.689713,"marketCap":28381033},{"date":"2025-03-14","current":-0.470191,"twenty":-9.227225,"median":-5.670316,"eighty":-0.675243,"marketCap":22443611},{"date":"2025-03-21","current":-0.53152,"twenty":-9.18875,"median":-5.509385,"eighty":-0.665195,"marketCap":25371039},{"date":"2025-03-28","current":-0.482968,"twenty":-9.161872,"median":-5.425609,"eighty":-0.655147,"marketCap":23053492},{"date":"2025-04-04","current":-0.408861,"twenty":-9.091808,"median":-5.407973,"eighty":-0.643893,"marketCap":19516184},{"date":"2025-04-11","current":-0.429305,"twenty":-9.050837,"median":-5.380674,"eighty":-0.631433,"marketCap":20491993},{"date":"2025-04-17","current":-0.472746,"twenty":-9.045443,"median":-5.362133,"eighty":-0.622992,"marketCap":22565587},{"date":"2025-04-25","current":-0.472746,"twenty":-9.037388,"median":-5.336421,"eighty":-0.57878,"marketCap":22565587},{"date":"2025-05-02","current":-0.39864,"twenty":-8.919003,"median":-5.165991,"eighty":-0.546852,"marketCap":19028279},{"date":"2025-05-09","current":-0.314156,"twenty":-8.857697,"median":-5.050076,"eighty":-0.534567,"marketCap":18784327},{"date":"2025-05-16","current":-0.354955,"twenty":-8.778159,"median":-5.035734,"eighty":-0.528965,"marketCap":21223850},{"date":"2025-05-23","current":-0.336596,"twenty":-8.694918,"median":-4.992187,"eighty":-0.51491,"marketCap":20126064},{"date":"2025-05-30","current":-0.385555,"twenty":-8.584144,"median":-4.945951,"eighty":-0.506094,"marketCap":23053492},{"date":"2025-06-06","current":-0.375355,"twenty":-8.389867,"median":-4.923647,"eighty":-0.48773,"marketCap":22443611},{"date":"2025-06-13","current":-0.346796,"twenty":-8.305941,"median":-4.87898,"eighty":-0.485012,"marketCap":20735945},{"date":"2025-06-20","current":-0.325376,"twenty":-8.294103,"median":-4.767993,"eighty":-0.472746,"marketCap":19455195},{"date":"2025-06-27","current":-0.316196,"twenty":-8.276767,"median":-4.744886,"eighty":-0.463426,"marketCap":18906303},{"date":"2025-07-03","current":-0.293756,"twenty":-8.257318,"median":-4.726928,"eighty":-0.447751,"marketCap":17564565},{"date":"2025-07-11","current":-0.677271,"twenty":-8.238715,"median":-4.597074,"eighty":-0.434085,"marketCap":40496081},{"date":"2025-07-18","current":-0.473274,"twenty":-8.204468,"median":-4.511228,"eighty":-0.43275,"marketCap":28298466},{"date":"2025-07-25","current":-0.471234,"twenty":-8.162188,"median":-4.172821,"eighty":-0.434085,"marketCap":28176490},{"date":"2025-08-01","current":-0.452874,"twenty":-8.09158,"median":-3.876104,"eighty":-0.433118,"marketCap":27078705},{"date":"2025-08-08","current":-0.417439,"twenty":-7.990847,"median":-0.854102,"eighty":-0.431093,"marketCap":21833730},{"date":"2025-08-15","current":-0.438428,"twenty":-7.911731,"median":-0.739552,"eighty":-0.423091,"marketCap":22931516},{"date":"2025-08-22","current":-0.437262,"twenty":-7.782512,"median":-0.719455,"eighty":-0.423091,"marketCap":22870528},{"date":"2025-08-29","current":-0.412775,"twenty":-7.72332,"median":-0.705388,"eighty":-0.422172,"marketCap":21589778},{"date":"2025-09-05","current":-0.387122,"twenty":-7.662014,"median":-0.692325,"eighty":-0.419594,"marketCap":20248040},{"date":"2025-09-12","current":-0.438428,"twenty":-7.579145,"median":-0.689311,"eighty":-0.417439,"marketCap":22931516},{"date":"2025-09-19","current":-0.405779,"twenty":-7.530963,"median":-0.677262,"eighty":-0.417439,"marketCap":21223850},{"date":"2025-09-26","current":-0.438428,"twenty":-7.458231,"median":-0.675243,"eighty":-0.417439,"marketCap":22931516},{"date":"2025-10-03","current":-0.482737,"twenty":-7.286722,"median":-0.66821,"eighty":-0.417768,"marketCap":25249063},{"date":"2025-10-10","current":-0.755588,"twenty":-7.269646,"median":-0.665195,"eighty":-0.419083,"marketCap":39520272},{"date":"2025-10-17","current":-0.839542,"twenty":-7.219361,"median":-0.673234,"eighty":-0.419594,"marketCap":43911414},{"date":"2025-10-24","current":-0.652977,"twenty":-7.152225,"median":-0.675243,"eighty":-0.421731,"marketCap":34153322},{"date":"2025-10-31","current":-0.643649,"twenty":-7.071889,"median":-0.671224,"eighty":-0.422103,"marketCap":33665417},{"date":"2025-11-07","current":-0.541038,"twenty":-6.870028,"median":-0.665195,"eighty":-0.422103,"marketCap":28298466},{"date":"2025-11-14","current":-0.515386,"twenty":-6.825412,"median":-0.656232,"eighty":-0.422103,"marketCap":26956729},{"date":"2025-11-21","current":-0.564098,"twenty":-6.824371,"median":-0.655309,"eighty":-0.422137,"marketCap":23747399},{"date":"2025-11-28","current":-0.640091,"twenty":-6.820206,"median":-0.655147,"eighty":-0.422275,"marketCap":26946530},{"date":"2025-12-05","current":-1.058049,"twenty":-6.768144,"median":-0.655228,"eighty":-0.424315,"marketCap":44541754},{"date":"2025-12-12","current":-0.929447,"twenty":-6.739119,"median":-0.659166,"eighty":-0.424435,"marketCap":39127839},{"date":"2025-12-19","current":-0.885605,"twenty":-6.703603,"median":-0.665195,"eighty":-0.429305,"marketCap":37282186},{"date":"2025-12-26","current":-0.935292,"twenty":-6.685845,"median":-0.66881,"eighty":-0.430327,"marketCap":39373926},{"date":"2026-01-02","current":-0.970366,"twenty":-6.655355,"median":-0.673234,"eighty":-0.431091,"marketCap":40850448},{"date":"2026-01-09","current":-1.046358,"twenty":-6.628277,"median":-0.677253,"eighty":-0.431431,"marketCap":44049580},{"date":"2026-01-16","current":-1.052204,"twenty":-6.612282,"median":-0.686296,"eighty":-0.431688,"marketCap":44295667},{"date":"2026-01-23","current":-1.198343,"twenty":-6.573971,"median":-0.69132,"eighty":-0.432106,"marketCap":50447843},{"date":"2026-01-30","current":-1.174961,"twenty":-6.526024,"median":-0.692622,"eighty":-0.433118,"marketCap":49463495},{"date":"2026-02-06","current":-1.131119,"twenty":-6.49406,"median":-0.700332,"eighty":-0.434085,"marketCap":47617842},{"date":"2026-02-13","current":-1.119428,"twenty":-6.432796,"median":-0.709407,"eighty":-0.434889,"marketCap":47125668},{"date":"2026-02-20","current":-1.417082,"twenty":-6.392718,"median":-0.721465,"eighty":-0.436096,"marketCap":59656302},{"date":"2026-02-27","current":-1.579698,"twenty":-6.311552,"median":-0.741418,"eighty":-0.436271,"marketCap":66502107},{"date":"2026-03-06","current":-1.506686,"twenty":-6.300499,"median":-0.776576,"eighty":-0.437029,"marketCap":63428480},{"date":"2026-03-13","current":3.453654,"twenty":-6.263811,"median":-0.766082,"eighty":-0.436096,"marketCap":102991419},{"date":"2026-03-20","current":3.272141,"twenty":-6.239871,"median":-0.739264,"eighty":-0.431983,"marketCap":97578518},{"date":"2026-03-23","current":3.277047,"twenty":-6.234829,"median":-0.737399,"eighty":-0.431603,"marketCap":97724812}],"updateTime":1774405934053},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"QTTB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588720304","title":"BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720304","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720304?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:03","pubTimestamp":1764594181,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097Dec 1  - Q32 BIO SELLS COMPLEMENT INHIBITOR ADX-097Q32 BIO INC - $12 MILLION PAYMENTS EXPECTED TO EXTEND CASH RUNWAY INTO SECOND HALF OF 2027Q32 BIO INC - ELIGIBLE FOR UP TO $592 MILLION INCLUDING ROYALTIESSource text: ID:nPn4S4bM2a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA5XFQDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","AKBA","BK4139"],"gpt_icon":0},{"id":"2588727118","title":"Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727118","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727118?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:46","pubTimestamp":1764593160,"startTime":"0","endTime":"0","summary":"Q32 Bio said it sold the lead product candidate from its tissue-targeted complement inhibitor platform to Akebia Therapeutics.The Waltham, Mass., biotech company said Monday it will receive $12 million in upfront payments and a near-term milestone. Q32 Bio said it will be eligible to receive a total of up to $592 million, pending the achievement of certain development, regulatory and commercial milestones, in addition to tiered royalties of up to a mid-teen percent of annual net sales.The transaction will strengthen the company's cash position, extending its runway into the second half of 2027, while also enabling it to focus on the advancement of bempikibart, its treatment for autoimmune and inflammatory diseases, Q32 Bio said.Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat.Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of complement-mediated rare kidney diseases.\"While our commercial and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","BK4139","QTTB"],"gpt_icon":0},{"id":"2588119727","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588119727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588119727?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:45","pubTimestamp":1764593159,"startTime":"0","endTime":"0","summary":"Q32 Bio  shares were 71% higher pre-bell Monday after the company said it has sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .Belite Bio  stock was up 17% after the company said that a late-stage trial of Tinlarebant to treat Stargardt eye disease met its primary efficacy endpoint.Canadian Solar  shares were 13% higher after the company said it will resume direct oversight of its US operations.INVO Fertility  stock was up 12% after the company said it plans to acquire fertility clinic Family Beginnings.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","IVF","BK4519","AKBA","BLTE","BK4082","BK4139","BK4588","BK4585","QTTB","BK4141","BK4007"],"gpt_icon":1},{"id":"2588082724","title":"Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2588082724","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588082724?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590425,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. announced the signing of an Asset Purchase Agreement with Q32 Bio, under which Akebia acquired global rights to Q32 Bio's ADX-097, now referred to as AKB-097. As part of the agreement, Akebia made an upfront payment of $7.0 million to Q32 Bio and will make an additional $3.0 million payment six months after the closing. The agreement also includes provisions for potential additional development, regulatory, and commercial milestone payments, as well as tiered royalties on annual net sales of AKB-097.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1kPh8k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","QTTB","NDAQ","BK4139","AKBA","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","BK4585","BK4112","LU2210149790.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2588787724","title":"Akebia Announces Establishment of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588787724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588787724?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139","AKBA"],"gpt_icon":0},{"id":"2588724049","title":"Akebia Therapeutics: Phase 2 Basket Trial Planned to Evaluate Complement Inhibitor in Multiple Rare Kidney Disease Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724049?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AKBA","BK4139","QTTB"],"gpt_icon":0},{"id":"2588724046","title":"Akebia Therapeutics Inc: Both Trials Planned to Start Treating Subjects in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724046?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AKBA","QTTB"],"gpt_icon":0},{"id":"2588247797","title":"Akebia Therapeutics: Acquires Next Generation Tissue-Targeted C3d-Factor H Fusion Protein Complement Inhibitor From Q32 Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2588247797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588247797?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AKBA","BK4139","QTTB"],"gpt_icon":0},{"id":"2588240297","title":"Akebia Therapeutics Inc: Phase 2 Trial of Praliciguat Initiated in Focal Segmental Glomerulosclerosis (Fsgs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588240297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588240297?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AKBA","QTTB"],"gpt_icon":0},{"id":"2588772472","title":"Q32 Bio Inc - Eligible for up to $592 Mln Including Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772472?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA5XFQDT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","AKBA","BK4139"],"gpt_icon":0},{"id":"2588724776","title":"Q32 Bio Inc - $12 Mln Payments Expected to Extend Cash Runway Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724776?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA5XFQDT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AKBA","QTTB","BK4139"],"gpt_icon":0},{"id":"2588724011","title":"Press Release: Q32 Bio Sells Complement Inhibitor ADX-097","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724011","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724011?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --. -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 --. -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these programs --. Q32 Bio's tissue-targeted complement platform is designed to inhibit complement activation in the tissue while minimizing systemic complement blockade, a key differentiator versus current complement therapeutics.  The platform is proprietary to Q32 Bio and developed with foundational science from the University of Colorado Anschutz Medical Campus. Beyond ADX-097, discovery and earlier development efforts include ADX-096, a C3d mAb -- CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications as well as potential utility ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","AA","AKBA","BK4585","ADX","QTTB","BK4153"],"gpt_icon":0},{"id":"2584291776","title":"Q32 Bio (QTTB) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584291776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584291776?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:55","pubTimestamp":1763387734,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jay Olson maintained a Buy rating on Q32 Bio on November 14 and set a price target of $20.00. The company’s shares closed last ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/q32-bio-qttb-receives-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/q32-bio-qttb-receives-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4127","QTTB","OPY"],"gpt_icon":0},{"id":"2584819643","title":"Wells Fargo Remains a Hold on Q32 Bio (QTTB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584819643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584819643?lang=en_us&edition=fundamental","pubTime":"2025-11-17 16:25","pubTimestamp":1763367937,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila maintained a Hold rating on Q32 Bio on November 14 and set a price target of $10.00. The company’s shares closed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-hold-on-q32-bio-qttb-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-hold-on-q32-bio-qttb-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765489.SGD","IE0002270589.USD","LU0048573561.USD","LU0208291251.USD","BK4559","LU0683600562.USD","LU0868494617.USD","LU1267930490.SGD","LU0256863811.USD","LU1074936037.SGD","LU1668664300.SGD","LU1791807156.HKD","IE000M9KFDE8.USD","LU0310800379.SGD","QTTB","LU1280957306.USD","LU0648001328.SGD","LU0052756011.USD","LU0175139822.USD","BK4139","IE00B19Z3581.USD","LU0742534661.SGD","LU1267930227.SGD","LU0128525929.USD","LU1506573853.SGD","LU0149725797.USD","LU0417517546.SGD","LU1814569148.SGD","LU1267930573.SGD","LU0787776722.HKD","LU0640476718.USD","LU0942090050.USD","LU1035773651.USD","LU0310799852.SGD","LU0980610538.SGD","LU0130517989.USD","LU2461242641.AUD","BK4585","LU1069347547.HKD","LU0251142724.SGD","LU0477156953.USD","LU0868494708.USD","LU0267386448.USD","LU0251131958.USD","LU0029864427.USD","LU0971096721.USD","BK4501","LU0314106906.USD","LU0708994859.HKD","LU0106831901.USD"],"gpt_icon":0},{"id":"2583562399","title":"Q32 Bio Inc. reports Q3 net loss of $7.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562399","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562399?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:59","pubTimestamp":1763035163,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc. reported a net loss of $7.4 million, or $0.60 per share, for the third quarter of 2025, compared to a net loss of $17.6 million, or $1.46 per share, for the same period in 2024. Research and development expenses decreased to $3.6 million from $14.3 million, primarily due to lower development costs for bempikibart, reduced expenses from the discontinued ADX-097 program, and lower personnel-related costs. General and administrative expenses were $4.0 million, down from $4.5 million, mainly due to decreased personnel and professional service costs. As of September 30, 2025, cash and cash equivalents totaled $49.0 million, expected to fund operations into 2027. The company completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial, with a topline data readout expected in mid-2026, and continues dosing in the Part A open-label extension.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLjjQVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2583564768","title":"Q32 Bio Inc - Q3 Net Loss $7.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564768?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:59","pubTimestamp":1763035140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5GVW4S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2583564430","title":"Q32 Bio Inc Qtrly EPS $-0.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564430?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:59","pubTimestamp":1763035140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5GVW4S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2583050564","title":"Q32 Bio Inc: Cash and Cash Equivalents Sufficient to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2583050564","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583050564?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:59","pubTimestamp":1763035140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5GVW4S:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2580219461","title":"Q32 Bio Inc  expected to post a loss of $1.19 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219461","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219461?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:13","pubTimestamp":1762179186,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc  expected to post a loss of $1.19 a share - Earnings Preview Q32 Bio Inc QTTB.OQ QTTB.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF19G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2577154821","title":"Q32 Bio Completes Enrollment in Phase 2a Alopecia Areata Trial of Bempikibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2577154821","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577154821?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:59","pubTimestamp":1761044356,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc. has announced the completion of enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata . The trial enrolled a total of 33 patients, exceeding the initial target of approximately 20 due to increased demand. Bempikibart is a fully human anti-IL-7Rα antibody designed to block IL-7 and TSLP signaling. Preliminary pharmacokinetic data indicate that steady state drug concentration in patients is achieved at least nine weeks earlier in Part B compared to Part A, due to the inclusion of a loading regimen. Topline results from Part B of the SIGNAL-AA trial are expected to be reported in mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDLrTbRc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}]}}